



## EDITORIAL

# Guardians of safety: The vital role of good distribution practices in pharmaceutical product quality and supply chain security

Niraj S. Patil<sup>1</sup>, Animesh Ranjan<sup>1</sup>, Komal<sup>2</sup>, Amandeep Singh<sup>2</sup>

<sup>1</sup>Department of Regulatory Affairs, ISF College of Pharmacy, Moga, Punjab, India, <sup>2</sup>Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India

In an age where pharmaceutical products crisscross the globe, ensuring the integrity, quality, and safety of these life-saving medicines demands unwavering vigilance. Good distribution practices (GDPs) serve as the silent sentinel that stands between patients and potential harm. This editorial embarks on a journey into the world of pharmaceutical distribution, where GDP emerges as the unsung hero, safeguarding not only the efficacy of medications but also the health and well-being of patients. The pharmaceutical supply chain is an intricate web, spanning continents and involving numerous stakeholders.<sup>[1]</sup> The responsibility of GDP, often hidden from the public eye, is to guarantee that this web remains unbroken, secure, and reliable. It is a system where a minor lapse can have catastrophic consequences. This editorial dives deep into GDP's role in the pharmaceutical industry, exploring its historical evolution, the critical nexus between product quality and safety, regulatory oversight, technological innovations, and emerging trends that are shaping the future.

The foundation of GDP in the pharmaceutical industry is the crucial link; it provides between quality and safety.<sup>[2]</sup> Every pharmaceutical product that reaches the hands of a patient must be effective and free from harm. GDP ensures that this happens by imposing a set of stringent standards and practices throughout the distribution process.<sup>[3]</sup> It goes beyond merely moving products from point A to point B; it guarantees the preservation of a product's integrity and therapeutic value. The relationship between quality and safety is at the core of GDP. It is not enough for a medication to be safe if it has lost its potency due to improper storage or handling. Conversely, a product may be potent but unsafe if it is been exposed to conditions that could compromise its safety. GDP mandates the precise conditions, handling

protocols, and monitoring mechanisms necessary to uphold both facets. This is especially vital in a field where minor variations can have severe consequences. Real-world examples of GDP failures underscore the critical role this set of practices plays. We have seen cases where temperature-sensitive vaccines lost their efficacy due to inadequate cold chain management, rendering millions of dollars' worth of medication ineffective. In other instances, counterfeit drugs infiltrated the supply chain, posing health risks to unsuspecting patients.<sup>[4]</sup> These examples serve as cautionary tales, emphasizing the paramount importance of adhering to GDP in every facet of pharmaceutical distribution.

GDP is not a mere set of rules; it serves as a lifeline for patients, diligently guarding their health. It ensures that medications are of the highest quality, untouched by degradation, contamination, or tampering. Patient well-being is intrinsically tied to the effectiveness of drugs, and GDP plays a pivotal role in maintaining this efficacy. Real-life scenarios underscore GDP's impact. Inadequate temperature control during insulin distribution, for instance, can endanger diabetic patients.<sup>[5]</sup> Similarly, improper vaccine storage can expose communities to preventable diseases. The pharmaceutical supply chain's complexity, essential for global demands, comes with vulnerabilities such as temperature fluctuations, theft, and counterfeit infiltration. In this intricate web, GDP stands as the protective shield, assuring that every product arrives at patients' doors with the same efficacy, securing their health from supply chain negligence.

### Address for Correspondence:

Dr. Amandeep Singh,

E-mail: ad4singh@gmail.com

### Access this article online

**Website:**

<http://isfcp-pharmaspire.com>

**DOI:**

10.56933/Pharmaspire.2023.15141

**Date of Submission:** 13 October 2023

**Date of Revision:** 31 October 2023

**Date of Acceptance:** 14 December 2023

GDP is the linchpin in addressing the supply chain challenge. It ensures the integrity of products as they navigate this intricate web.<sup>[6]</sup> By imposing rigorous protocols and standards, GDP minimizes the risks associated with supply chain vulnerabilities. It necessitates precise control over temperature, humidity, and other environmental factors to safeguard product quality. In addition, GDP implements security measures to prevent theft and tampering, effectively serving as a sentinel against counterfeits. The critical role of GDP in this context cannot be overstated. The consequences of a failure in supply chain integrity extend far beyond financial losses; they can have life-altering effects on patients.<sup>[7]</sup> In the pharmaceutical supply chain, GDP serves as the protective shield, ensuring that every product that leaves a manufacturer's facility arrives at a patient's doorstep in the same condition and with the same efficacy. GDP operates within a structured framework of regulatory oversight. The role of regulatory agencies in enforcing GDP standards is paramount in maintaining the highest levels of quality and safety in pharmaceutical distribution.<sup>[8]</sup> These agencies provide the legal backbone for GDP, ensuring that it is not merely a set of best practices but a set of mandatory requirements that must be adhered to.

Regulatory oversight encompasses various aspects, from defining and updating GDP guidelines to conducting inspections and audits to ensure compliance. The pharmaceutical industry operates on a global scale, which has led to a need for international coordination of these regulations.<sup>[9]</sup> The global landscape of GDP regulations is moving toward harmonization, with the aim of standardizing practices and requirements across borders. This harmonization simplifies compliance for companies that operate internationally and strengthens the consistency of GDP implementation. It also serves to enhance patient safety by minimizing the risks associated with varying standards in different regions. Regulatory agencies serve as the watchful guardians of patient safety, enforcers of quality standards, and proponents of continuous improvement within the pharmaceutical distribution industry.<sup>[10]</sup> They act as a vital part of the GDP ecosystem, reinforcing the importance of adhering to these standards and continuously improving them.

In the digital age, technology is revolutionizing pharmaceutical distribution through innovations such as the Internet of Things (IoT) and blockchain.<sup>[11]</sup> IoT allows real-time monitoring of factors such as temperature and humidity, reducing the risk of product compromise during transit. Meanwhile, blockchain technology creates a tamper-proof record of the entire supply chain, combating counterfeit infiltration and enhancing traceability. These technological advancements are essential tools for upholding GDP and ensuring the safety and quality of pharmaceutical products. While GDP compliance is mandatory, companies striving for excellence go beyond the basics. They implement

state-of-the-art monitoring systems, controlled storage facilities, and comprehensive personnel training, reducing wastage, cost, and environmental impact. Striving for excellence in GDP is not just a regulatory obligation; it is a smart business decision. Companies that excel in GDP earn trust from stakeholders and regulators, leading to increased market share and growth opportunities.<sup>[12]</sup> In a rapidly evolving pharmaceutical landscape, embracing technological advancements and achieving excellence in GDP are a strategic path to success.

The pharmaceutical industry faces numerous challenges in its global supply chain, including the complexity of managing diverse regulations in multiple countries, counterfeiting threats, and the need for temperature-sensitive product handling. Varying GDP standards between nations and the adherence to international guidelines add compliance complexities. Maintaining secure and accurate distribution records is essential, but data integrity and security are ongoing concerns. Third-party logistic providers pose challenges in ensuring GDP compliance and quality commitments. The costs and technical challenges of implementing real-time tracking technologies are substantial. During public health emergencies, maintaining product quality and security becomes crucial. In addition, political and geopolitical issues can disrupt the pharmaceutical supply chain, impacting the flow of products.

## CONCLUSION

In an era of global pharmaceutical distribution, the silent sentinel of GDP stands as the unsung hero, safeguarding the integrity and safety of life-saving medications. GDP bridges the crucial link between quality and safety, ensuring that pharmaceutical products reach patients unharmed. It is a lifeline for patient health, guaranteeing medication efficacy and protection from potential risks. The pharmaceutical supply chain's complexity requires meticulous oversight, and GDP serves as the linchpin, mitigating supply chain vulnerabilities. Regulatory agencies enforce GDP standards globally, and technological innovations such as IoT and blockchain further enhance pharmaceutical distribution's safety and quality. Striving for excellence in GDP is a smart business choice, reducing wastage, earning trust, and ensuring a secure pharmaceutical future.

## FUTURE PERSPECTIVES

Future perspectives in pharmaceutical distribution include the continued integration of advanced technologies such as IoT and blockchain to enhance safety and quality. The harmonization of GDP regulations globally will streamline compliance and improve patient safety. Companies are likely to increasingly focus on achieving excellence in GDP, not just as a regulatory requirement but as a means

to reduce wastage, cut costs, and gain trust, resulting in growth opportunities. Embracing these trends will be pivotal in ensuring the integrity of pharmaceutical products in an ever-evolving landscape.

### ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

### CONSENT FOR PUBLICATION

Not applicable.

### AVAILABILITY OF DATA AND MATERIAL

Not applicable.

### COMPETING INTERESTS

Not applicable.

### FUNDING

Not applicable.

### ACKNOWLEDGMENTS

Not applicable.

### REFERENCES

1. Abdallah S, Nizamuddin N. Blockchain-based solution for pharma supply chain industry. *Comput Ind Eng* 2023;177:108997.
2. O'Mahony D, McDermott O, Lynch A, Cormican K. The impact of serialisation on operational efficiency and productivity in pharmaceutical sites: A literature review. *Cogent Eng* 2023;10:2231729.
3. Amicone D, Cannas A, Marci A, Tortora G. A smart capsule equipped with artificial intelligence for autonomous delivery of medical material through drones. *Appl Sci* 2021;11:7976.
4. White CM. Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United States. *J Am Pharm Assoc* (2003) 2021;61:e93-8.
5. Al-Shihabi F, Moore A, Chowdhury TA. Diabetes and climate change. *Diabet Med* 2023;40:e14971.
6. Leibbrandt B. Vertical Integration in Sub-Saharan Africa's Wheat Market: Achieving Competitive Advantage, Benefits, and Challenges for Commodity Traders.
7. York O, Sebata D. A review of supply chain management practices: The case of Botswana state-owned enterprises (SOE). In: *Understanding the Dynamics of New Normal for Supply Chains: Post COVID Opportunities and Challenges*. Cham: Springer; 2022. p. 139-59.
8. Kumar J, Ramkishan A, Venkatesh MP. Bridging the gap: Aligning GMP requirements for generic manufacturing across the US, EU and Japan. *Int J Pharm Invest* 2023;13:432-9.
9. Kerr WA. The COVID-19 pandemic and agriculture: Short-and long-run implications for international trade relations. *Can J Agric Econ/Rev Can D'agroeconomie* 2020;68:225-9.
10. Da Silveira PB, Kovacic WE, editors. *Global Competition Enforcement: New Players, New Challenges*. Netherlands: Kluwer Law International BV; 2019.
11. Ratta P, Kaur A, Sharma S, Shabaz M, Dhiman G. Application of blockchain and internet of things in healthcare and medical sector: Applications, challenges, and future perspectives. *J Food Qual* 2021;2021:7608296.
12. Villena VH, Dhanorkar S. How institutional pressures and managerial incentives elicit carbon transparency in global supply chains. *J Oper Manage* 2020;66:697-734.